Skip to main content
. 2021 Mar 25;9(3):e001504. doi: 10.1136/jitc-2020-001504

Figure 3.

Figure 3

(A) Plasma ctDNA change at the first follow-up blood sampling according to the response to pembrolizumab±chemotherapy. (B) Plasma ctDNA change at the first follow-up according to whether the progression-free survival (PFS) was ≥6 months or <6 months to pembrolizumab±chemotherapy. Y-axis is truncated at 100%. AF, allele fraction; ctDNA, circulating tumor DNA.